11/26
02:09 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
07:10 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
11/26
06:30 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
11/21
05:31 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/14
08:09 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
09:01 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
06:30 am
imux
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/7
08:45 am
imux
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
10/29
06:30 am
imux
Immunic to Participate in Industry and Investor Conferences in November
Medium
Report
Immunic to Participate in Industry and Investor Conferences in November
10/22
04:04 am
imux
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage [Yahoo! Finance]
Low
Report
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage [Yahoo! Finance]
10/18
07:31 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Low
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
10/8
12:25 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunic (NASDAQ:IMUX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/2
10:42 am
imux
Positive Signs As Multiple Insiders Buy Immunic Stock [Yahoo! Finance]
Low
Report
Positive Signs As Multiple Insiders Buy Immunic Stock [Yahoo! Finance]
10/1
06:38 am
imux
Immunic to Participate in Scientific and Investor Conferences in October [Yahoo! Finance]
Medium
Report
Immunic to Participate in Scientific and Investor Conferences in October [Yahoo! Finance]
10/1
06:30 am
imux
Immunic to Participate in Scientific and Investor Conferences in October
High
Report
Immunic to Participate in Scientific and Investor Conferences in October
9/29
08:05 am
imux
Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
9/26
08:05 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/25
08:06 am
imux
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
9/25
06:40 am
imux
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis [Yahoo! Finance]
Low
Report
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis [Yahoo! Finance]
9/25
06:30 am
imux
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Low
Report
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
9/9
06:53 am
imux
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis [Yahoo! Finance]
Low
Report
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis [Yahoo! Finance]
9/9
06:30 am
imux
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Low
Report
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis